Skip to content

BioMarin Pharmaceuticals BMRN Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent

Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent at other companies

ATI logo
ATIATI
$18.38M+183%
Lennar logo
LennarLEN
-$715K-269%
Kimberly-Clark logo
Kimberly-ClarkKMB
-$28M-121%
Welltower logo
WelltowerWELL
-$56.32M-212%
Alcoa logo
AlcoaAA
$34M
Baxter International logo
Baxter InternationalBAX
$35.25M+130%

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's other comprehensive income (loss), tax, portion attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's other comprehensive income (loss), tax, portion attributable to parent?
BioMarin Pharmaceuticals (BMRN) reported other comprehensive income (loss), tax, portion attributable to parent of -$1.12M in Q1 2026.
How has BioMarin Pharmaceuticals's other comprehensive income (loss), tax, portion attributable to parent changed year-over-year?
BioMarin Pharmaceuticals's other comprehensive income (loss), tax, portion attributable to parent decreased by 425.8% year-over-year, from $345K to -$1.12M.